IL6 and chronic kidney disease: Currently, a large trial, ZEUS (Zlitivekimab Cardiovascular Outcomes Study), is ongoing to evaluate the effects of ziltivekimab in people with CVD, CKD, and inflammation,81 which will provide valuable outcomes for the effectiveness of IL-6 targeting in CVD and, particularly, patients with CKD.